The Liver’s Innate Regenerative Power
The liver is composed of cells called hepatocytes that are normally quiescent, meaning they rarely divide [1.4.2]. However, when the liver sustains an injury, such as from toxins, viral infections, or physical removal (partial hepatectomy), it triggers a complex and highly organized process of regeneration [1.4.2, 1.4.3]. This process can be divided into three main stages: initiation (priming), progression (proliferation), and termination [1.4.1, 1.4.2]. During these phases, a cascade of cytokines and growth factors, like Tumor Necrosis Factor-α (TNF-α), Interleukin-6 (IL-6), and Hepatocyte Growth Factor (HGF), activate signaling pathways that prompt the remaining healthy hepatocytes to re-enter the cell cycle and divide [1.4.2, 1.4.5]. This allows the liver to restore its original mass and function, a capacity that is crucial for treatments like partial liver transplantation [1.4.1, 1.4.5]. When this regenerative ability is impaired or overwhelmed by chronic injury, harmful scarring (fibrosis) can occur, potentially leading to cirrhosis [1.7.1]. Therefore, pharmacological strategies often focus on either protecting liver cells from damage, reducing fibrosis, or stimulating these natural regenerative pathways.
Newly Approved and Breakthrough Therapies
Recent years have seen significant breakthroughs, particularly for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease that causes inflammation and fibrosis [1.2.3].
- Resmetirom (Rezdiffra): In March 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Resmetirom, the first medication specifically for MASH with moderate to advanced liver fibrosis [1.2.3, 1.5.2]. Resmetirom is a daily pill that works by activating a thyroid hormone receptor in the liver, which boosts the organ's metabolism of fatty acids [1.2.3, 1.3.5]. Clinical trials demonstrated that Resmetirom could reduce liver fat, inflammation, and scarring [1.2.4, 1.5.5]. In a Phase 3 trial, about 26% of participants in the highest-dose group showed an improvement in fibrosis by at least one stage, compared to 14% in the placebo group [1.2.3, 1.5.1].
- Semaglutide (Wegovy): Originally known as a weight-loss and diabetes drug, Semaglutide received FDA approval in August 2025 for treating MASH in adults with moderate-to-advanced liver scarring [1.9.2, 1.3.6]. This GLP-1 receptor agonist helps manage blood sugar, reduces appetite, and promotes weight loss, which in turn reduces the metabolic stress on the liver [1.3.6]. Studies have shown it can halt and even reverse the progression of MASH by reducing both liver swelling and scarring [1.3.6, 1.9.2].
Investigational Drugs in the Pipeline
Researchers are actively exploring new molecular targets to stimulate liver regeneration and reverse damage.
- HRX215: A promising investigational drug, HRX215, works by inhibiting a protein called MKK4 in liver cells, which appears to trigger the liver's self-healing function [1.2.1, 1.3.1]. Preclinical studies in animal models were highly successful, showing that HRX215 increased liver regeneration and prevented liver failure even after the removal of 85% of the organ [1.2.1]. A Phase 1 study in healthy volunteers found it to be safe and well-tolerated, paving the way for further clinical trials to establish its efficacy in humans [1.2.1]. This drug holds potential for patients with liver tumors or those undergoing transplants [1.2.1].
- ION224: Another investigational drug, ION224, targets a liver enzyme known as DGAT2, which is central to fat production and storage [1.9.1]. A Phase IIb clinical trial published in August 2025 showed that by blocking this enzyme, ION224 effectively reduced fat accumulation and inflammation in patients with MASH [1.9.1].
- Pemvidutide: In June 2025, it was announced that pemvidutide met its primary endpoint in a Phase 2b trial for MASH, demonstrating significant MASH resolution without worsening fibrosis in a majority of participants [1.9.4].
Supporting Medications and Supplements
While not direct regenerative agents, several existing medications and supplements play a vital role in protecting the liver and creating an environment where it can heal itself.
- Ursodeoxycholic Acid (UDCA): UDCA is a hydrophilic bile acid and the only FDA-approved drug for treating certain cholestatic liver diseases like primary biliary cholangitis [1.7.1, 1.7.5]. Research shows that UDCA alleviates liver fibrosis by promoting liver regeneration [1.7.1]. It works by activating the ID1-WNT2/HGF signaling pathway, which enhances hepatocyte proliferation [1.7.1]. Studies in living liver donors who received UDCA post-surgery showed significant improvements in liver function tests compared to those who did not [1.7.2].
- Metformin: This common diabetes medication has been studied for its effects on liver disease with mixed but promising results [1.6.1]. Metformin improves insulin sensitivity and can reduce hepatic glucose production [1.6.1]. While its direct impact on reversing MASH histology is debated, it has shown positive effects in reducing the risk of hepatocellular carcinoma (HCC) and improving outcomes in patients with cirrhosis [1.6.1, 1.6.2, 1.6.5]. Its mechanism involves activating AMPK, which helps regulate lipid metabolism and reduce inflammation [1.6.2].
- Silymarin (Milk Thistle): Silymarin is a natural extract from milk thistle seeds known for its antioxidant, anti-inflammatory, and antifibrotic properties [1.8.1, 1.8.2]. It protects liver cells from damage by scavenging free radicals and inhibiting inflammatory pathways [1.8.1]. While clinical trial results have been varied, some studies show that silymarin can improve liver function tests and reduce fibrosis progression, particularly when initiated in the early stages of liver disease [1.8.1, 1.8.2]. Higher doses have shown more promising results in improving fibrosis in patients with NASH [1.8.2].
Comparison of Liver Support Medications
| Medication/Supplement | Primary Mechanism | Status for Liver Regeneration | Primary Use/Indication |
|---|---|---|---|
| Resmetirom (Rezdiffra) | Activates thyroid hormone receptor in the liver to metabolize fat [1.2.3] | Approved for MASH; shown to improve fibrosis [1.5.1] | MASH with moderate to advanced fibrosis [1.2.4] |
| Semaglutide (Wegovy) | GLP-1 receptor agonist; improves metabolic parameters and promotes weight loss [1.3.6] | Approved for MASH; can reverse scarring [1.9.2] | MASH with moderate-to-advanced scarring, Type 2 Diabetes, Obesity [1.9.2] |
| Ursodeoxycholic Acid (UDCA) | Hydrophilic bile acid; activates pro-regenerative signaling pathways (ID1-WNT2/HGF) [1.7.1] | Supportive; promotes an environment for regeneration and reduces fibrosis [1.7.1] | Primary Biliary Cholangitis and other cholestatic diseases [1.7.5] |
| Metformin | Activates AMPK, improves insulin sensitivity, reduces hepatic glucose production [1.6.2] | Supportive/Investigational; mixed results on histology, but may reduce HCC risk [1.6.1, 1.6.3] | Type 2 Diabetes [1.6.1] |
| Silymarin (Milk Thistle) | Antioxidant, anti-inflammatory, and antifibrotic effects [1.8.1] | Supportive (Supplement); protects liver cells and may improve fibrosis [1.8.2, 1.8.4] | Herbal supplement for liver support [1.8.4] |
Conclusion
While the concept of a single drug that fully regenerates a damaged liver remains in the realm of future medicine, the landscape of pharmacological treatment has evolved dramatically. The recent FDA approvals of Resmetirom and Semaglutide mark a pivotal moment, offering the first targeted treatments that can reverse fibrosis in MASH patients [1.2.3, 1.9.2]. Alongside these breakthroughs, investigational drugs like HRX215 show the potential to directly trigger the liver's innate healing mechanisms [1.2.1]. Established medications like UDCA and supplements such as Silymarin continue to play a crucial supportive role by protecting the liver and fostering an environment conducive to its natural regeneration [1.7.1, 1.8.2]. The combination of these approaches provides growing hope for millions affected by chronic liver disease.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult with a healthcare professional for diagnosis and treatment of any medical condition.
For more information on the latest advancements, you can visit the Mayo Clinic News Network.
